94 related articles for article (PubMed ID: 11276023)
1. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy.
Nio Y; Dong M; Iguchi C; Yamasawa K; Toga T; Itakura M; Tamura K
J Surg Oncol; 2001 Mar; 76(3):188-96. PubMed ID: 11276023
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas.
Nio Y; Iguchi C; Yamasawa K; Sasaki S; Takamura M; Toga T; Dong M; Itakura M; Tamura K
Pancreas; 2001 Apr; 22(3):230-9. PubMed ID: 11291923
[TBL] [Abstract][Full Text] [Related]
3. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Pancreas; 1999 Mar; 18(2):117-26. PubMed ID: 10090408
[TBL] [Abstract][Full Text] [Related]
4. p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Anticancer Res; 1998; 18(5B):3773-9. PubMed ID: 9854494
[TBL] [Abstract][Full Text] [Related]
5. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas.
Nio Y; Omori H; Hashimoto K; Itakura M; Koike M; Yano S; Toga T; Higami T; Maruyama R
Anticancer Res; 2005; 25(5):3523-9. PubMed ID: 16101174
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer.
Dong M; Zhou JP; Zhang H; Guo KJ; Tian YL; Dong YT
World J Gastroenterol; 2005 May; 11(18):2744-7. PubMed ID: 15884114
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
9. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Takamura M; Nio Y; Yamasawa K; Dong M; Yamaguchi K; Itakura M
Anticancer Drugs; 2002 Jan; 13(1):75-85. PubMed ID: 11914644
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of pBcl-2 and pBax expression in primary invasive ductal pancreatic cancer between Chinese and Japanese patients].
Zhou JP; Dong M; Nio Y; Kong FM; Zheng XY; Guo KJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):611-4. PubMed ID: 16274043
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas.
Nio Y; Omori H; Toga T; Hashimoto K; Itakura M; Koike M; Yano S; Higami T
Anticancer Drugs; 2003 Apr; 14(4):313-9. PubMed ID: 12679736
[TBL] [Abstract][Full Text] [Related]
12. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome.
Toga T; Nio Y; Hashimoto K; Higami T; Maruyama R
Anticancer Res; 2004; 24(2C):1173-8. PubMed ID: 15154643
[TBL] [Abstract][Full Text] [Related]
13. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 expression in pancreas development and pancreatic cancer progression.
Campani D; Esposito I; Boggi U; Cecchetti D; Menicagli M; De Negri F; Colizzi L; Del Chiaro M; Mosca F; Fornaciari G; Bevilacqua G
J Pathol; 2001 Aug; 194(4):444-50. PubMed ID: 11523052
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
16. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes.
Dong M; Dong Q; Zhang H; Zhou J; Tian Y; Dong Y
J Surg Oncol; 2007 Mar; 95(4):332-6. PubMed ID: 17230496
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Minari Y; Nio Y; Hirahara N; Dong M
Cancer Chemother Pharmacol; 2001 May; 47(5):415-22. PubMed ID: 11391857
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma.
Chen D; Zheng X; Kang D; Yan B; Liu X; Gao Y; Zhang K
Med Princ Pract; 2012; 21(1):68-73. PubMed ID: 22024503
[TBL] [Abstract][Full Text] [Related]
19. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
[TBL] [Abstract][Full Text] [Related]
20. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M
Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
